歌礼制药-B已正式向美国食品药品监督管理局（FDA）递交ASC30_39 FDC的新药临床试验（IND）申请。该药物是一种口服小分子固定剂量复方制剂，将GLP-1R激动剂与选择性胰淀素受体激动剂合二为一，拟用于肥胖症治疗，并具备成为同类首创（first-in-class）疗法的潜力。
歌礼制药-B已正式向美国食品药品监督管理局（FDA）递交ASC30_39 FDC的新药临床试验（IND）申请。该药物是一种口服小分子固定剂量复方制剂，将GLP-1R激动剂与选择性胰淀素受体激动剂合二为一，拟用于肥胖症治疗，并具备成为同类首创（first-in-class）疗法的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.